Phenylboronic acid selectively inhibits human prostate and breast cancer cell migration and decreases viability.
We compared the in vitro effect of boric acid (BA) versus phenylboronic acid (PBA) on the migration of prostate and breast cancer cell lines and non-tumorigenic cells from the same tissues. Treatment at 24 hours with BA (< or =500 microM) did not inhibit chemotaxis on fibronectin in any cell line. However, treatment over the same time course with concentrations of PBA as low as 1 muM significantly inhibited cancer cell migration without effecting non-tumorigenic cell lines. The compounds did not affect cell adhesion or viability at 24 hours but did alter morphology; both decreased cancer cell viability at eight days. These results suggest that PBA is more potent than BA in targeting the metastatic and proliferative properties of cancer cells.
Bradke
Tiffany M
TM
Department of Biology, Rensselaer Polytechnic Institute, Troy, New York 12180-3596, USA.
Hall
Casey
C
Carper
Stephen W
SW
Plopper
George E
GE
D001888:Boric Acids / Q000494:pharmacology; D001897:Boronic Acids / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000473:pathology*; D002448:Cell Adhesion / Q000187:drug effects; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects; D005353:Fibronectins / Q000378:metabolism; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000473:pathology*; D013997:Time Factors
D001888:Boric Acids; D001897:Boronic Acids; D005353:Fibronectins; C010686:benzeneboronic acid; C032688:boric acid